BSBE(SZ:300406)2017-04-26 16:00Financial Performance - Total revenue for Q1 2017 was CNY 139,786,179.63, a decrease of 6.47% compared to CNY 149,453,344.08 in the same period last year[8] - Net profit attributable to shareholders was CNY 51,553,789.60, down 19.56% from CNY 64,089,098.91 year-on-year[8] - Operating profit for Q1 2017 was CNY 62,720,480.11, down from CNY 74,417,786.56 in the previous year, indicating a decline of 15.5%[50] - The total profit for Q1 2017 was CNY 60,625,957.35, a decrease of 18.5% from CNY 74,386,729.37 in Q1 2016[55] - The net profit for Q1 2017 was CNY 51,532,063.75, down 19.6% from CNY 64,083,561.08 in Q1 2016[55] - Basic earnings per share for Q1 2017 were CNY 0.1034, compared to CNY 0.1283 in Q1 2016, reflecting a decline of 19.1%[57] Cash Flow - Net cash flow from operating activities increased by 91.37% to CNY 23,564,935.56, compared to CNY 12,313,634.31 in the previous year[8] - The cash flow from operating activities for Q1 2017 was CNY 23,564,935.56, an increase of 91.1% from CNY 12,313,634.31 in the previous year[61] - The company reported a net increase in cash and cash equivalents of CNY 33,932,011.98, compared to CNY 3,217,027.60 in the previous period[66] - The ending balance of cash and cash equivalents was CNY 817,105,495.99, up from CNY 690,672,497.37 year-on-year[66] - Cash inflow from financing activities was CNY 10,604,609.96, with a net cash flow of CNY 10,603,673.16 after outflows[66] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 1,532,348,985.14, reflecting a 4.16% increase from CNY 1,471,114,424.73 at the end of the previous year[8] - Total liabilities amounted to CNY 91,005,311.60, compared to CNY 83,078,639.25 at the start of the year, showing an increase of 9.5%[48] - The equity attributable to shareholders of the parent company was CNY 1,441,204,402.09, up from CNY 1,388,022,858.81, reflecting a growth of 3.8%[48] Market and Product Development - The proportion of revenue from in vitro diagnostic reagents was 93.10% in Q1 2017, indicating a continued reliance on this segment[10] - The domestic market for immunodiagnostics is growing at over 15%, presenting both opportunities and challenges for the company[11] - The company plans to enhance its competitiveness by increasing investment in new product development and expanding its marketing network[10] - The company is focused on expanding its market share through innovative marketing strategies and increased R&D investment[26] - The company completed the development of several testing kits, including total antioxidant activity and superoxide dismutase, and obtained medical device registration certificates[27] Operational Efficiency - The average return on equity decreased to 3.65% from 5.31% in the previous year, indicating a decline in profitability[8] - The company faces risks related to the reliance on imported raw materials, which accounted for 22.83% of total raw material purchases in Q1 2017[14] - The company aims to reduce dependence on imported raw materials by increasing investment in the development of self-sourced materials[15] - Management expenses increased by 56.29%, from RMB 12.69 million to RMB 19.83 million, primarily due to higher R&D and depreciation costs[24] Research and Development - The company has a stable R&D team of 57 members, with 49.1% holding master's degrees or above, ensuring a solid foundation for future R&D outcomes[27] - In Q1 2017, the company obtained and applied for 2 international and domestic patents, with 27 new products in the registration application process[26] - The company has made significant progress in the national "863 Program" project, with successful outcomes in various medical device registrations[26] Shareholder Returns - The company plans to distribute a cash dividend of CNY 3.00 per share, totaling CNY 150,248,582.7, based on a total share capital of 500,828,609 shares[35]